Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
All News
Advertisement
Advertisement
Your daily dose of the clinical news you may have missed.
Family physician Teresa Lovins, MD, explains how primary care clinicians can determine when to manage depression and when urgent referral is needed.
.jpg?w=350&fit=crop&auto=format)
Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.
Teresa Lovins, MD, describes the PHQ-9, GAD-7, and other brief screeners that help family physicians identify depression, anxiety, ADHD, and bipolar disorder in everyday practice.
Analysis presented at AHA Hypertension 2025 showed fewer than 6% of US adults use salt substitutes, despite their potential to improve BP control.
Your daily dose of the clinical news you may have missed.
This week’s podcast covers psoriasis trial results, intranasal insulin, COVID-19 booster safety, GLP-1 use in diabetes, and RSV vaccine uptake.
A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.
Your daily dose of the clinical news you may have missed.
Advertisement
With the surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.
Research reveals that older age and lower aerobic fitness significantly increase the risk of arrhythmias, highlighting the need for early screening and fitness maintenance.
Your daily dose of the clinical news you may have missed.
Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.
FDA clears MiniMed 780G for integration with Abbott’s Instinct sensor and approves its use in insulin-requiring T2D, expanding automated insulin delivery options.
Your daily dose of the clinical news you may have missed.
At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
.jpg?w=350&fit=crop&auto=format)
Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.
At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.
Your daily dose of the clinical news you may have missed.
Advertisement
Advertisement
Advertisement
